Curis (CRIS) Net Cash Flow (2010 - 2026)
Curis' (CRIS) quarterly Net Cash Flow came in at $9.9 million in Q1 2026, up 3388.07% YoY from $285000.0 in Q1 2025, and up 347.35% on a QoQ basis from -$4.0 million in Q4 2025.
Curis (CRIS) Net Cash Flow (2010 - 2026) Analysis & Trends
Curis (CRIS) has 17 years of Net Cash Flow data on file, last reported at $9.9 million in Q1 2026.
- Quarterly Net Cash Flow rose 3388.07% year-over-year to $9.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.3 million (up 45.43% YoY) and the FY2025 annual result came in at -$14.9 million, down 123.44% from the prior year.
- Net Cash Flow advanced to $9.9 million in Q1 2026, from -$4.0 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $15.4 million in Q2 2022 to a low of -$21.5 million in Q1 2022.
- A 5-year average of -$1.5 million and a median of -$857000.0 in 2024 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2025 — Net Cash Flow slumped 368.96% — and 2026, when it jumped 3388.07%.
- Tracing CRIS's Net Cash Flow over 5 years: stood at -$10.2 million in 2022, then soared by 121.71% to $2.2 million in 2023, then plunged by 138.73% to -$857000.0 in 2024, then tumbled by 368.96% to -$4.0 million in 2025, then soared by 347.35% to $9.9 million in 2026.
- The last three Net Cash Flow figures came in at $9.9 million (Q1 2026), -$4.0 million (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Curis | 3.27 Mn | -2.35 Mn | - | -9.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.94 Mn |
| Mar 31, 2026 | 9.94 Mn |
| Dec 31, 2025 | -4.02 Mn |
| Dec 31, 2025 | -4.02 Mn |
| Sep 30, 2025 | -1.06 Mn |
| Sep 30, 2025 | -1.06 Mn |
| Jun 30, 2025 | -10.14 Mn |
| Jun 30, 2025 | -10.14 Mn |
| Mar 31, 2025 | 285,000.00 |
| Mar 31, 2025 | 285,000.00 |
| Dec 31, 2024 | -857,000.00 |
| Dec 31, 2024 | -857,000.00 |
| Sep 30, 2024 | 10.86 Mn |
| Sep 30, 2024 | 10.86 Mn |
| Jun 30, 2024 | -19.96 Mn |
| Jun 30, 2024 | -19.96 Mn |
| Mar 31, 2024 | 3.28 Mn |
| Mar 31, 2024 | 3.28 Mn |
| Dec 31, 2023 | 2.21 Mn |
| Dec 31, 2023 | 2.21 Mn |